While type 1 and type 2 diabetes typically occupy distinct places in healthcare, research is showing an increase of patients ...
In an escalation of India's unfolding GLP-1 patent war, Novo Nordisk has approached the Delhi High Court to restrain Sun ...
The CMS has just announced a new list of medicines selected for this program that includes Novo Nordisk's Wegovy, Ozempic, ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...
Zacks Investment Research on MSN
LLY trading above 50 & 200-day SMAs for 2 months: How to play the stock
Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) ...
There have been some interesting failures recently in Alzheimer’s trials. Two are notable because they’re aimed outside the ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today positive topline results in its 13-week Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the ...
Since its discovery 30 years ago, NRF2 has emerged as a master regulator of cellular homeostasis and has been implicated in a broad range of pathologies. This Review analyses NRF2 regulation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results